Dermata Therapeutics (DRMA) Share-based Compensation (2020 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Share-based Compensation of $400000.0 for Q1 2026, up 975.59% year-over-year from $37189.0 in Q1 2025, and up 1257.36% quarter-over-quarter from $29469.0 in Q4 2025.
Dermata Therapeutics (DRMA) Share-based Compensation (2020 - 2026) Analysis & Trends
Dermata Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $400000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 975.59% year-over-year to $400000.0; the TTM figure through Mar 2026 stood at $400000.0 (up 271.73% YoY), while the FY2025 annual figure was $200000.0, down 69.59% from the prior year.
- Share-based Compensation for Q1 2026 stood at $400000.0, up from $29469.0 in the prior quarter.
- The five-year high for Share-based Compensation was $587234.0 in Q1 2024, with the low at $19608.0 in Q2 2024.
- The 5-year median for Share-based Compensation is $128468.0 (2023), against an average of $142979.0.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation sank 93.67% in 2025, then surged 975.59% in 2026.
- Dermata Therapeutics' Share-based Compensation stood at $220890.0 in 2022, then plunged by 41.84% to $128468.0 in 2023, then tumbled by 76.79% to $29815.0 in 2024, then retreated by 1.16% to $29469.0 in 2025, then soared by 1257.36% to $400000.0 in 2026.
- Business Quant data shows DRMA's Share-based Compensation at $400000.0 in Q1 2026, $29469.0 in Q4 2025, and $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Dermata Therapeutics | 5.33 Mn | 5.33 Mn | - | 43,278.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 400,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Dec 31, 2025 | 29,469.00 |
| Dec 31, 2025 | 29,469.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 39,234.00 |
| Jun 30, 2025 | 39,234.00 |
| Mar 31, 2025 | 37,189.00 |
| Mar 31, 2025 | 37,189.00 |
| Dec 31, 2024 | 29,815.00 |
| Dec 31, 2024 | 29,815.00 |
| Sep 30, 2024 | 20,992.00 |
| Sep 30, 2024 | 20,992.00 |
| Jun 30, 2024 | 19,608.00 |
| Jun 30, 2024 | 19,608.00 |
| Mar 31, 2024 | 587,234.00 |
| Mar 31, 2024 | 587,234.00 |
| Dec 31, 2023 | 128,468.00 |
| Dec 31, 2023 | 128,468.00 |